In this week’s issue of The Savvy Diabetic:
-
- Drug Cuts Albuminuria in Type 1 Diabetic Kidney Disease, Too
- Tandem Diabetes Care launches Mobi pump on Android phones
- Sandoz receives US FDA approval to expand Enzeevu® for retinal indications
- Bridging the Diabetes Care Divide
Drug Cuts Albuminuria in Type 1 Diabetic Kidney Disease, Too by Kristen Monaco for MedPage.com, 4 March 2026.
Finerenone (Kerendia) significantly reduced albuminuria in adults with type 1 diabetes and chronic kidney disease (CKD), meeting the primary endpoint of the phase III FINE-ONE trial.”These effects appeared to be similar across subgroups of participants with the lowest eGFR [estimated glomerular filtration rate] or highest urinary albumin-to-creatinine ratio — participants who are at very high risk for adverse kidney and cardiovascular outcomes,” the team reported in the New England Journal of Medicine.
It’s been 30 years since a new drug to delay kidney disease progression in adults with type 1 diabetes was successful in a clinical trial — the last being the ACE inhibitor captopril in 1993 — noted accompanying editorial authors Aleksandra Kukla, MD, and Marie C. Hogan, MD, PhD, both of the Mayo Clinic in Rochester, Minnesota. While FINE-ONE is “promising,” they said a larger, longer trial is needed to demonstrate a sustained kidney-function benefit.
“The surge of therapies for diabetic kidney disease in persons with type 2 diabetes gives the nephrology community reason to hope that an accelerated drug-development pipeline will now address the full spectrum of diabetic kidney disease in persons with type 1 diabetes — including the substantial population with low or normal urinary albumin-to-creatinine ratios who remain at risk but were excluded from the FINE-ONE trial,” Kukla and Hogan pointed out.
Tandem Diabetes Care launches Mobi pump on Android phones bySean Whooley for DrugDeliveryBusiness.com, 4 March 2026.
Tandem Diabetes Care announced that it made its Mobi automated insulin delivery system available with Android devices. San Diego-based Tandem said Mobi, the world’s smallest, durable automated insulin delivery system, can now be used with compatible Android smartphones in the U.S. via the Tandem Mobi mobile app. The pump, which pairs with Tandem’s Control-IQ+ algorithm, previously worked with iOS software. At the time of the clearance, it said it would commence a limited rollout before the full launch — now underway — this year.
“By expanding to Android, we’re broadening our reach to bring the benefits of Tandem Mobi to even more people living with diabetes,” said John Sheridan, president and chief executive officer. “It’s an exciting milestone that underscores our commitment to delivering choice in diabetes technology, enabling more people to experience the convenience and flexibility that Tandem Mobi provides.”
Read more: Tandem Diabetes Care launches Mobi pump on Android phones
Sandoz receives US FDA approval to expand Enzeevu® label for multiple retinal indications by Sandoz.com, 18 February 2026.
Sandoz, the global leader in affordable medicines, announced that the US Food and Drug Administration (FDA) has approved an expanded label for Enzeevu® (aflibercept-abzv), to include multiple retinal indications. The most recent approval expands the Enzeevu® label indications to include macular edema following retinal vein occlusion (RVO), diabetic retinopathy (DR), and diabetic macular edema (DME), along with the previously approved indication of nAMD. This expansion offers retina specialists a clinically-proven aflibercept biosimilar option to treat more patients across these retinal diseases.
Keren Haruvi, President of Sandoz North America, said: “More than 30 million people in the US are living with retinal diseases that can lead to irreversible vision loss or blindness. With this expanded label, we’re broadening our ability to deliver affordable care to those impacted by these devastating diseases.”
Read more: Sandoz receives US FDA approval to expand Enzeevu® label for multiple retinal indications
Bridging the Diabetes Care Divide by Marissa Town for ChildrenwithDiabetes.com, 18 February 2026.
Access to specialized diabetes providers has long been a challenge that many endocrinologists have discussed. Since endocrinology is a specialty that performs few procedures, it is among the lower-paying specialties in medicine. Additionally, the fellowship program is longer than those of some other specialties. When considering the amount of debt that most physicians accumulate in their schooling and training, it shouldn’t be much of a surprise that this is an issue.
-
-
-
- Simply not enough endocrinologists: In addition to the reasons listed above, there are also not enough endocrinology fellowship programs available. The endocrinology fellowship programs that do exist are often located at academic institutions in metropolitan areas.
- Endocrinologists who “don’t like diabetes.”: I’ve met several endocrinologists, both pediatric and adult, who choose to see patients who have other endocrine conditions and avoid treating people with diabetes. Diabetes is a difficult, self-managed condition that is affected by innumerable variables. The tools that are used to manage it are constantly changing, requiring medical professionals to learn new devices and software regularly.
-
-
Strategies to meet the needs:
-
- Utilizing APRNs/PAs
- Primary Care
- Diabetologist
- Remote patient monitoring
- Multidisciplinary team
Recruiting new diabetes medical professionals: This is something I often hear from leading endocrinologists in the U.S. and globally: we need to focus on recruiting the next generation of the diabetes care team.
Read more: Bridging the Diabetes Care Divide
